References
- Archer R. A., Blanchard W. B., Day W. A., Johnson D. W., Lavagnino E. R., Ryan C. W., Baldwin J. Cannabinoids III. Synthetic approaches to 9-ketocannabinoids. The total synthesis of nabilone. Journal of Organic Chemistry 1977; 42: 2277–2284
- Billings R. E., Whitaker G. W., McMahon R. E. The stereoselective enzymic reduction of the synthetic 9-ketocannabinoid, nabilone, in vivo, in isolated liver cells and in liver homogenate. Xenobiotica 1980; 10: 33–36
- Hanasono G. K., Sullivan H. R., Emmerson J. L. A species comparison of the toxicity of nabilone, a new synthetic cannabinoid. Pharmacologist 1984; 26: 233
- Hanasono G. K., Sullivan H. R., Gries C. L., Jordan W. H., Emmerson J. L. A species comparison of the toxicity of nabilone, a new synthetic cannabinoid. Fundamental and Applied Toxicology 1987; 7, in press
- Herman T. S., Elnhorn L. H., Jones S. E., Nagy C., Chester A. B., Dean J. S., Furnas B., Williams S. D., Leigh S. A., Dorr R. T., Moon T. E. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New England Journal of Medicine 1979; 300: 1295–1297
- Lemberger L., Rowe H. Clinical pharmacology of nabilone, a cannibinol derivative. Clinical Pharmacology and Therapeutics 1975; 18: 720–726
- Rubin A., Lembercer L., Warrick P., Crabtree R. E., Sullivan H. R., Rose H., Obermeyer B. D. Physiologic disposition of nabilone, a cannibinol derivative in man. Clinical Pharmacology and Therapeutics 1977; 22: 85–91
- Stark P., Archer R. A. Preclinical pharmacologic profile of a psychoactive cannabinoid. Pharmacologist 1975; 17: 210
- Sullivan H. R., Kau D. L. K., Wood P. G. Pharmacokinetics of nabilone, a psychrotropically active 9-ketocannabinoid in the dog. Utilization of quantitative selected ion monitoring and deuterium labeling. Biomedical Mass Spectrmetry 1978; 5: 296–301